… that metastatic, castration-resistant prostate cancers with DNA-repair defects would … to
poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibition with olaparib. …

… Progress in understanding the biology of advanced prostate cancer and mechanisms of …
before or after chemotherapy in metastatic castration-resistant prostate cancer (mCRPC; refs. 1–…

… to induce clinical responses in patients with metastatic PC expressing HR DNA-repair
defects. In fact, olaparib has been designed to target DNA repair pathway. If PARP enzyme is …

… TOPARP-B also assessed different doses of olaparib, and correlated different genomic …
activity of olaparib against metastatic prostate cancer with defective DNA repair secondary to …

… (mCRPC) harbor mutations in genes encoding DNA repair proteins … Olaparib (olap) inhibits
PARP and showed activity in a post hoc analysis in mCRPC patients with DNA repair defects …

… of the genomic landscape of prostate cancer, with special attention to alterations in …
opportunities for advanced prostate cancer based upon targeting these DNA-repair pathways. …

… DNA repair genes. In this manuscript, we review the current knowledge on DNA repair defects
in prostate cancer … can be targeted towards a personalized prostate cancer management. …

… have been recognized to be frequently dysregulated in advanced stages of prostate
cancer. DNA-repair defects in prostate cancer represents a clinically relevant disease subset. …

… defects), and in this study the authors postulated that prostate cancer cells carrying
mutations in known DNA repair genes would be particularly responsive to …

… We also recommend that olaparib or rucaparib be considered relatively early in the treatment
sequence in metastatic castration-resistant prostate cancer patients with BRCA1 or BRCA2 …